Urinary tract infection

Studies Show Continued Efficacy of New UTI Vaccine

Retrieved on: 
Saturday, May 4, 2024
UTI, Vaccination, Interview, Woman, American Urological Association, Abstract (summary), Abstract, MD, Urology, Research, Urinary tract infection, Urogynecology, Communication, Infection, Annual general meeting, SAN, Female, Northwell Health

SAN ANTONIO, May 04, 2024 (GLOBE NEWSWIRE) -- Abstracts being presented at the American Urological Association's Annual Meeting discuss a new urinary tract infection (UTI) treatment as well as the UTI implications of weight management drugs.

Key Points: 
  • SAN ANTONIO, May 04, 2024 (GLOBE NEWSWIRE) -- Abstracts being presented at the American Urological Association's Annual Meeting discuss a new urinary tract infection (UTI) treatment as well as the UTI implications of weight management drugs.
  • Researchers will present their study findings covering important updates on UTI in San Antonio, Texas, from May 3 to 6.
  • “Fifty percent of women develop a urinary tract infection in their lifetime and a quarter will experience recurrent infections.
  • Treating this can be challenging for the patient and for providers,” said Dr. Lee.

Future of PF-07923568 in the Fight Against Respiratory Syncytial Virus - Market Size, Forecast, and Emerging Insights to 2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 2, 2024
Health, Pharmaceutical, SWOT, Respiratory syncytial virus, Urinary tract infection, Disease, Patient, European, RSV, Global health, Pharmaceutical industry

In a significant development for the pharmaceutical industry, a comprehensive new report provides in-depth analysis and projections for the market potential of PF-07923568, a cutting-edge treatment for Respiratory Syncytial Virus (RSV).

Key Points: 
  • In a significant development for the pharmaceutical industry, a comprehensive new report provides in-depth analysis and projections for the market potential of PF-07923568, a cutting-edge treatment for Respiratory Syncytial Virus (RSV).
  • Respiratory syncytial virus is a major cause of respiratory illness worldwide, and the development of PF-07923568 represents a significant milestone in the fight against this pervasive virus.
  • The healthcare and pharmaceutical industries are closely monitoring the evolution of the PF-07923568 market landscape, which promises to play a significant role in advancing the treatment of Respiratory Syncytial Virus globally.
  • As medical science continues to push boundaries, reports such as these provide critical insights that help shape the future of healthcare delivery and patient care.

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer

Retrieved on: 
Friday, May 3, 2024
FDA, Congress, Cancer, Urinary tract infection, Urinary diversion, Safety, Carcinoma, Survival, Johnson & Johnson, Immunotherapy, CRS, Abstract, Cohort, BCG, Disease, Bladder cancer, Dysuria, Patient, Metastasis, Medicine, NMIBC, AUA, Biopsy, BTD, Urination, Interim, Food and Drug Administration, SAN, Pharmaceutical industry

SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of investigational TAR-200 monotherapy in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ, who are ineligible for, or decline, radical cystectomy. These data were featured today in a plenary session (Abstract #P2-01) at the 2024 American Urological Association Annual Meeting (AUA) taking place May 3-6, 2024, in San Antonio, Texas.

Key Points: 
  • "These results address an area of high unmet need for bladder sparing therapies in this patient population."
  • Results included an evaluation of 85 patients (median age of 71 years old: range 40-88; 32.9% with concurrent papillary disease) who received TAR-200 monotherapy.
  • The centrally confirmed complete response (CR) rate was 82.8% by urine cytology and/or biopsy (95% confidence interval [CI], 70.6-91.4).
  • Seven patients (8.2%) had Grade 3 or higher TRAEs and four patients (4.7%) had one or more serious TRAEs.

A link between breast changes and … UTIs?

Retrieved on: 
Thursday, May 2, 2024
UTI, CSHL, Urinary tract infection, TIMP1, Mouse, Risk, Pregnancy, Woman, Health, Cold Spring Harbor Laboratory, Research, Human, Metastasis, Cold, Infection, Menopause, Breast cancer, SPRING, Medical imaging

COLD SPRING HARBOR, N.Y., May 2, 2024 /PRNewswire/ -- Women's health is often talked about in terms of major, life-altering events like pregnancy and menopause. A new study from Cold Spring Harbor Laboratory (CSHL) underscores the importance of considering everyday occurrences' impact on women's well-being.

Key Points: 
  • The scientists found that UTIs in mice can provoke a bodily response that results in structural changes in breast tissue.
  • Cyrill notes that the breast changes that the team observed in mice with UTIs "were not directly caused by the infection itself.
  • Hormonal changes during pregnancy and menopause are known factors that can influence breast cancer risk .
  • They're now looking at how other changes women go through in their lifetimes might unexpectedly influence breast tissue.

National Poll Shows Women Are Missing Out on Vacations, Work, and Social Events Due to Gynecological Conditions

Retrieved on: 
Thursday, May 2, 2024
Generation Z, Polycystic ovary syndrome, Public opinion, Premenstrual syndrome, PMS, Infant, Advertising, Woman, Health, Research, Generation X, Marketing, OnePoll, Endometriosis, ESOMAR, Depression, Market Research Society, Mental, Silent Generation, Millennials, Generation, Quality of life, Anxiety, Menopause, Urinary tract infection, Opinion, Knowledge, Nursing

"Millions of women silently struggle every day with gynecological conditions, some as common as PMS and UTIs," said Liz Weir, chief marketing officer at LevLane.

Key Points: 
  • "Millions of women silently struggle every day with gynecological conditions, some as common as PMS and UTIs," said Liz Weir, chief marketing officer at LevLane.
  • Reasons for absence: Premenstrual/Period symptoms (26%), UTIs (18%) and endometriosis (6%) were common causes for missing work.
  • Baby boomers had the highest cancellation rate due to gynecological conditions, while Generation Z had the lowest.
  • This random double-opt-in survey of 1,000 American women was commissioned by LevLane between April 12 and April 16, 2024.

Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive Care

Retrieved on: 
Thursday, April 25, 2024
Patent portfolio, Dentistry, Zinc, Security (finance), Tannin, Entrepreneurship, Erectile dysfunction, Pharynx, Urinary tract infection, Acquisition, HPV, Global health, Marketing, PPA, Infection, ODT, Pharmaceutical industry

Dallas, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce that it has acquired a global patent portfolio for a pioneering oral solution and application aimed to combat and prevent a spectrum of infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV) (the “Patent Portfolio”) from Intramont Technologies, Inc. (“Intramont”), pursuant to a Patent Purchase Agreement (“PPA”).

Key Points: 
  • We believe that the acquired technology represents a breakthrough in preventive care.
  • The acquired technology is protected by a global patent portfolio including US and international patent rights.
  • The keys to what we believe are the effectiveness of this oral health innovation are its unique ingredients and formulation.
  • Through working to commercialize this technology, we aim to unlock significant value for our shareholders while advancing global health and addressing significant market needs."

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024

Retrieved on: 
Thursday, April 18, 2024
Infection, University of Southern California, Medical microbiology, University, Mycobacteroides abscessus, Tuberculosis, Epidemiology, ESCMID, ECCMID, Erasmus MC, Urinary tract infection, Science, MAC, Antimycobacterial, Mycobacterium avium complex, Clinical pharmacy, Immunity, TB, National Jewish Health, Division, Pharmaceutical industry

BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, today announced that three new pre-clinical studies with NUZYRA® (omadacycline) will be presented at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global, formerly ECCMID).

Key Points: 
  • BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, today announced that three new pre-clinical studies with NUZYRA® (omadacycline) will be presented at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global, formerly ECCMID).
  • The hybrid conference will be held April 27-30 at the Fira Gran Via in Barcelona, Spain.
  • “Paratek continues to invest in science to further our understanding of NUZYRA, as well as explore its future utility in addressing additional unmet patient needs,” said Randy Brenner, chief development and regulatory officer of Paratek.
  • “Next week’s ESCMID presentations include a study assessing the potential immunomodulating properties of NUZYRA in addition to its antibacterial activity.

Renovion Announces Positive Top-Line Results from Phase 2 CLIMB Study of ARINA-1 (RVN-301) in Patients with Non-Cystic Fibrosis Bronchiectasis

Retrieved on: 
Tuesday, April 30, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hemoptysis, MCID, Inflammation, Safety, Mucus, QOL, Professor, Bronchiectasis, MD, Doctor of Philosophy, Conference, Mycobacterium, Sputum, Periodic breathing, Urinary tract infection, CAAT, Disease, Chronic cough, Patient, Principal, Aes, Diagnosis, Inc., ITT, American Thoracic Society, Quality of life, Asthma, Bronchitis, National Jewish Health, Division, Infection, COPD, Pharmaceutical industry

The CLIMB study was a randomized double-blind placebo-controlled study to assess the safety and efficacy of ARINA-1 in NCFBE.

Key Points: 
  • The CLIMB study was a randomized double-blind placebo-controlled study to assess the safety and efficacy of ARINA-1 in NCFBE.
  • Participants were randomized (7:3, treatment:placebo), and 40 participants completed the study, with 29 completing in the ARINA-1 arm and 11 in the placebo (0.9% saline) arm.
  • Topline results from the intention-to-treat (ITT) population demonstrate that ARINA-1 is safe and improves quality of life (QOL) in individuals with NCFBE who experience mucus symptoms.
  • Renovion will discuss study results at the American Thoracic Society Meeting (May 17-22) and present findings at the World Bronchiectasis Conference (July 4-6) in Dundee, Scotland.

Global Expansion in Clinical Laboratory Molecular Diagnostic Markets for Infectious Diseases: A Comprehensive Guide to Current Trends and Future Forecasts to 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 30, 2024
Infectious Diseases, Health, Medical Devices, Diagnosis, Infection, Climate change, Genomics, Urinary tract infection, Pandemic, Research, Biotechnology, Face, Vaccine

The "Global Clinical Laboratory Molecular Diagnostic for Infectious Disease Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Clinical Laboratory Molecular Diagnostic for Infectious Disease Markets" report has been added to ResearchAndMarkets.com's offering.
  • The clinical laboratory molecular diagnostics sector for infectious diseases is undergoing a significant transformation.
  • A comprehensive research publication, now available, delves into this rapidly growing field with a focus on current strategies, trends, and detailed forecasts spanning from 2023 to 2027.
  • Advancements in molecular diagnostics are experiencing a surge, especially in infectious disease testing.

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Retrieved on: 
Thursday, April 11, 2024
Doctor of Philosophy, UTI, Mortality, Randomized controlled trial, Urinary tract infection, Safety, High Risk, Sepsis, Immunotherapy, Septic shock, Ventilation, Community-acquired pneumonia, System, Patient, Therapy, Overalls, Infection, Pharmaceutical industry

Enlivex intends to consider a potential follow-on, randomized, controlled study of a solely High Risk UTI sepsis population.

Key Points: 
  • Enlivex intends to consider a potential follow-on, randomized, controlled study of a solely High Risk UTI sepsis population.
  • The study was designed for patients to be randomized with equal degree of SOFA scores across treatment and placebo groups.
  • Both of these patient attributes are associated with a significantly higher degree of difficulty of treatment and higher mortality rates.
  • Nes-Ziona, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive indication of effect and safety results from its Phase II study of Allocetra™ in patients with sepsis, in which 120 patients enrolled.